Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of 1,5-Pentanediol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,5-Pentanediol SCHEMBL923627 | 1.00 | CA5A (0.46) | CA5ACA5BGPR84FFAR1FFAR4 | |
| 1,6-Hexanediol SCHEMBL28157698 | 1.00 | CA5A (0.46) | CA5ACA5BGPR84FFAR1FFAR4 | |
| 1,4-Butanediol SCHEMBL445780 | 0.96 | CA5A (0.50) | CA5ACA5BGPR84FFAR1FFAR4 | |
| 1,4-Butanediol SCHEMBL924158 | 0.96 | CA5A (0.50) | CA5ACA5BGPR84FFAR1FFAR4 | |
| 1,4-Butanediol SCHEMBL921711 | 0.92 | CA5A (0.46) | CA5ACA5BGPR84FFAR1FFAR4 | |
| 1,4-Butanediol SCHEMBL27884349 | 0.92 | CA5A (0.46) | CA5ACA5BGPR84FFAR1FFAR4 | |
| Sulfuric Acid SCHEMBL920405 | 0.88 | CA5A (0.50) | CA5ACA5BGPR84FFAR1FFAR4 | |
| Sulfuric Acid SCHEMBL710960 | 0.88 | CA5A (0.50) | CA5ACA5BGPR84FFAR1FFAR4 | |
| SCHEMBL4300373 | 0.86 | LMNA (0.47) | GPR84FFAR1FFAR4LMNAALDH1A1 | |
| 1,5-Pentanediol SCHEMBL2966670 | 0.86 | LMNA (0.47) | GPR84FFAR1FFAR4LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098063-A1 | SECONDARY BATTERY AND ELECTRONIC DEVICE | 宁德新能源科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4148851-B1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE | NINGDE AMPEREX TECHNOLOGY LTD (CN) | 2026-05-13 | — | — | EP | disclosed |
| US-12537184-B2 | Electrochemical device and electronic device | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2026-01-27 | — | — | US | disclosed |
| US-20250105300-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE INCLUDING SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20250087739-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE INCLUDING SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-03-13 | — | — | US | disclosed |
| US-20250079498-A1 | ELECTROCHEMICAL DEVICE AND ELECTRONIC DEVICE INCLUDING SAME | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-03-06 | — | — | US | disclosed |
| US-12206114-B2 | Electrochemical device and electronic device including same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-01-21 | — | — | US | disclosed |
| US-12191442-B2 | Electrochemical device and electronic device including same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2025-01-07 | — | — | US | disclosed |
| US-12160000-B2 | Electrochemical device and electronic device including same | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2024-12-03 | — | — | US | disclosed |
| US-12148876-B2 | Electrochemical apparatus and electronic apparatus | NINGDE AMPEREX TECHNOLOGY LIMITED (CN) | 2024-11-19 | — | — | US | disclosed |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS INC. (CA) | 2009-07-02 | — | — | US | disclosed |
| EP-1996175-A4 | A CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | WARATAH PHARMACEUTICALS INC (CA) | 2009-06-10 | — | — | EP | disclosed |
| EP-1996175-A1 | A CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | Waratah Pharmaceuticals, Inc. (CA) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008124929-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF α-SYNUCLEINOPATHIES | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124930-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008124931-A1 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | MCLAURIN JOANNE (CA) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008034244-A1 | THE COMBINATION OF A CYCLOHEXANEHEXOL AND A NSAID FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | WARATAH PHARMACEUTICALS INC. (CA) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007101353-A1 | A CYCLOHEXANE POLYALCOHOL FORMULATION FOR TREATMENT OF DISORDERS OF PROTEIN AGGREGATION | WARATAH PHARMACEUTICALS INC. (CA) | 2007-09-13 | — | — | WO | disclosed |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | WARATAH PHARMACEUTICALS INC. (CA) | 2007-05-17 | — | — | US | disclosed |
| WO-2007041855-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERISED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | WARATAH PHARMACEUTICALS, INC. (CA) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12537184-B2 | Electrochemical device and electronic device | LBR, LAMTOR3, CACNA2D1 | CA5A 4026/4885CA5B 3670/4885GPR84 2972/4885 |
| US-20070111970-A1 | Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence | SCLY, SMOX, SMS | CA5A 4402/4885CA5B 4750/4885GPR84 2366/4885 |
| US-20090170957-A1 | SCYLLO-INOSITOL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE | SCLY, SCO2, SGMS2 | CA5A 3735/4885CA5B 4484/4885GPR84 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.